.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
McKinsey
Queensland Health
US Army
Fuji
Colorcon
Julphar
Baxter
Chinese Patent Office
Healthtrust

Generated: December 14, 2017

DrugPatentWatch Database Preview

Clevidipine - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for clevidipine and what is the scope of clevidipine patent protection?

Clevidipine
is the generic ingredient in one branded drug marketed by Chiesi Usa Inc and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Clevidipine has sixty-one patent family members in thirty-three countries and six supplementary protection certificates in six countries.

There are three drug master file entries for clevidipine. Three suppliers are listed for this compound.

Pharmacology for clevidipine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-002Aug 1, 2008RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-002Aug 1, 2008RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-003Nov 8, 2013RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-003Nov 8, 2013RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-001Aug 1, 2008RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-001Aug 1, 2008RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: clevidipine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-001Aug 1, 2008► Subscribe► Subscribe
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-003Nov 8, 2013► Subscribe► Subscribe
Chiesi Usa IncCLEVIPREXclevidipineEMULSION;INTRAVENOUS022156-002Aug 1, 2008► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: clevidipine

Country Document Number Estimated Expiration
Finland110429► Subscribe
Australia2011313852► Subscribe
China1049428► Subscribe
China1137269► Subscribe
Norway305656► Subscribe
Japan2014196322► Subscribe
Greece3034469► Subscribe
Hungary215591► Subscribe
Portugal2627173► Subscribe
New Zealand275915► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: CLEVIDIPINE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0726894/01Switzerland► SubscribePRODUCT NAME: RACEMISCHES CLEVIDIPINBUTYRAT; REGISTRATION NO/DATE: SWISSMEDIC 60117 11.06.2010
C0053France► SubscribePRODUCT NAME: CLEVIDIPINE; NAT. REGISTRATION NO/DATE: NL 37621 20120725; FIRST REGISTRATION: GB - PL 16881/0003 20111123
209Luxembourg► SubscribePRODUCT NAME: CLEVIDIPINE SOUS TOUTES LES FORMES PROCURANT UNE PROTECTION A PARTIR DU BREVET DE BASE
C/GB12/011United Kingdom► SubscribePRODUCT NAME: CLEVIDIPINE; REGISTERED: UK PL16881/0003 20111123
90008-0Sweden► SubscribePRODUCT NAME: CLEVIDIPINE; NAT. REG. NO/DATE: 42321 20120120; FIRST REG.: GB PL 16881/0003 20111123
00520Netherlands► SubscribePRODUCT NAME: CLEVIDIPINE; NAT. REGISTRATION NO/DATE: RVG 104771 20111129; FIRST REGISTRATION: PL 16881/0003 20111123
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
QuintilesIMS
Moodys
Merck
US Army
Boehringer Ingelheim
Cerilliant
Dow
Chinese Patent Office
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot